Owned pharmacy, single contracted partner, or several named partners. The difference only becomes visible when something goes wrong.
Compounded GLP-1 programs fall into three structures. Some own their dispensing pharmacy outright. Some contract with a single 503A partner. Some name several partners and route prescriptions by state, availability and prescriber direction.
The third structure is the most resilient and the rarest. NexLife names six partner facilities spanning 503A compounders and FDA-registered 503B outsourcing facilities; if one has a supply or regulatory problem, a prescription can be routed elsewhere. Programs with one owned facility have no such route, which is why a state action against a single pharmacy can interrupt every patient on a platform at once.
Ownership also determines who is accountable. When the platform and the pharmacy are the same company, a complaint about the medicine and a complaint about the service go to the same place, and the state board that licenses the pharmacy is the only external check. When they are separate, a patient has two routes and the pharmacy has an independent regulator with its own interest in the answer.
None of this appears in a pricing table, and fewer than a fifth of priced programs disclose enough to let you work out which structure you are buying into. The question to ask is simple and rarely asked: do you own the pharmacy that fills my prescription, and if not, how many do you work with?
We record what each program discloses in the open dataset, and the disclosure score on every provider page reflects whether the pharmacy is named at all.
Sources
- Provider published pharmacy disclosures, accessed 2026-08-05 — source
- FDA human drug compounding programme — source
Dated 2026-08-04. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.